Engineered vascular-targeting antibody-interferon-gamma fusion protein for cancer therapy.

@article{Ebbinghaus2005EngineeredVA,
  title={Engineered vascular-targeting antibody-interferon-gamma fusion protein for cancer therapy.},
  author={Christina Ebbinghaus and Roberto Ronca and M. Kaspar and Dragan Grabulovski and Alexander Berndt and Hartwig Kosmehl and Luciano Zardi and Dario Neri},
  journal={International journal of cancer},
  year={2005},
  volume={116 2},
  pages={304-13}
}
A number of cytokines are either approved drugs or are in advanced clinical trials, yet these biopharmaceuticals do not typically localize efficiently in solid tumors and manifest their therapeutic potential at the expense of severe side effects. The targeted delivery of cytokines to solid tumors is a promising avenue for increasing the therapeutic index of these biopharmaceuticals. We engineered a fusion protein between scFv(L19), a human antibody fragment specific to the EDB domain of… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 35 extracted citations

Vascular-targeted TNFα and IFNγ inhibits orthotopic colorectal tumor growth

Journal of Translational Medicine • 2016
View 2 Excerpts

Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution.

Proceedings of the National Academy of Sciences of the United States of America • 2015
View 1 Excerpt

Interferon-γ-induced necrosis: an antitumor biotherapeutic perspective.

Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research • 2013

Similar Papers

Loading similar papers…